Evidence map›Paper›PMID 20862509›Full record

Trial reportThe journal of headache and pain2011

Rizatriptan reduces vestibular-induced motion sickness in migraineurs.

Joseph M Furman, Dawn A Marcus, Carey D Balaban

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The journal of headache and pain, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00360282 (Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00360282 nacompletednot on this map

Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs

TypeinterventionalSponsorUniversity of PittsburghRan2006 to 2010Enrolled36ConditionsMigraineArmsRizatriptan, Placebo
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.

  1. Pharmacological interventions for acute attacks of vestibular migraine.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Trial
  3. Review
  4. Review
  5. Recent Trends in Treatment of Vestibular Migraine: A Systematic Review.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024
    Article
  6. Review
  7. Vestibular migraine.Arquivos de neuro-psiquiatria · 2022
    Article
  8. Vestibular migraine: the chameleon in vestibular disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Review
  9. Article
  10. Article
  11. Lasmiditan mechanism of action - review of a selective 5-HTThe journal of headache and pain · 2020
    Review
  12. Article
  13. Current Treatment Options: Vestibular Migraine.Current treatment options in neurology · 2017
    Review
  14. What is nausea? A historical analysis of changing views.Autonomic neuroscience : basic & clinical · 2017
    Review
  15. Review
  16. Review
  17. Motion Sickness: Current Knowledge and Recent Advance.CNS neuroscience & therapeutics · 2016
    Review
  18. Distribution of 5-HTFrontiers in neurology · 2016
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Joseph M FurmanDepartment of Otolaryngology, Eye and Ear Institute, University of Pittsburgh School of Medicine, 203 Lothrop Street, Pittsburgh, PA 15213, USA. furmanjm@upmc.edu
Dawn A Marcus
Carey D Balaban
University of Pittsburgh · USEye and Ear Foundation · US

Funding

VESTIBULO-CEREBELLAR CIRCUITSR01DC000739 · NIDCD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BALABAN, CAREY DAVID · 1990 to 2013
$3.4M
NIDCD NIH HHS R01 DC000739
6 · The paper itself

Abstract

A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo. Subjects included 25 migraineurs with or without migraine-related dizziness (23 females) aged 21-45 years (31.0 ± 7.8 years). Motion sickness was induced by off-vertical axis rotation in darkness, which stimulates both the semicircular canals and otolith organs of the vestibular apparatus. Results indicated that of the 15 subjects who experienced vestibular-induced motion sickness when pretreated with placebo, 13 showed a decrease in motion sickness following pretreatment with rizatriptan as compared to pretreatment with placebo (P < 0.02). This significant effect was not seen when subjects were exposed to more provocative vestibular stimulation. We conclude that the serotonin agonist, rizatriptan, reduces vestibular-induced motion sickness by influencing serotonergic vestibular-autonomic projections.

Indexed as

AdultDouble-Blind MethodFemaleHumansMaleMiddle AgedMigraine DisordersMotion SicknessSerotonin Receptor AgonistsTreatment OutcomeTriazolesTryptaminesVestibular DiseasesYoung AdultrizatriptanSerotonin Receptor AgonistsTriazolesTryptamines

Identifiers

PMID20862509
PMCPMC3072502
OpenAlexW2126488507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.